Koren Hyogene Kwag^1,*, Ibrahim Kak¹, Ying Li², Walid Khass¹, Alec McKechnie¹, Oksana Nulman¹, Brande Brown¹, Manoj Chhabra¹

Congenital Heart Disease, Vol.19, No.1, pp. 107-121, 2024, DOI:10.32604/chd.2024.045953

Abstract Objective: Accurate measurement of QT interval, the ventricular action potential from depolarization to repolarization, is important for the early detection of Long QT syndrome. The most effective QT correction (QTc) formula has yet to be determined in the pediatric population, although it has intrinsically greater extremes in heart rate (HR) and is more susceptible to errors in measurement. The authors of this study compare six different QTc methods (Bazett, Fridericia, Framingham, Hodges, Rautaharju, and a computer algorithm utilizing the Bazett formula) for consistency against variations in HR and RR interval. Methods: Descriptive Retrospective Study. We included participants from a pediatric… More >

GUSTAVO MARTÍN VILLOLDO¹, MARÍA TERESA POMBO², MARIANA ARIS³, JOAQUÍN CHEMI¹, PABLO MANDÓ³, SUPRIYA NAGARAJU⁴, JUAN CAMEAN¹, ADRIÁN BURIONI¹, DEBORAH EGEA¹, MORA AMAT⁵, JOSÉ LEÓN MELLADO³, JOSÉ MORDOH³, ALBERTO VILLARONGA¹, MARÍA MARCELA BARRIO^3,*

Oncology Research, Vol.31, No.2, pp. 207-220, 2023, DOI:10.32604/or.2023.028163

Abstract Intravesical Bacillus Calmette Guerin (BCG) is the gold standard therapy for intermediate/high-risk nonmuscle invasive bladder cancer (NMIBC). However, the response rate is ~60%, and 50% of non-responders will progress to muscle-invasive disease. BCG induces massive local infiltration of inflammatory cells (Th1) and ultimately cytotoxic tumor elimination. We searched for predictive biomarker of BCG response by analyzing tumor-infiltrating lymphocyte (TIL) polarization in the tumor microenvironment (TME) in pre-treatment biopsies. Pre-treatment biopsies from patients with NMIBC who received adequate intravesical instillation of BCG (n = 32) were evaluated retrospectively by immunohistochemistry. TME polarization was assessed by quantifying the T-Bet+ (Th1) and GATA-3+… More > Graphic Abstract

Alain J. Poncelet^1,*, Maureen Peers de Nieuwburgh², Stéphane Moniotte², Geoffroy de Beco¹, Karlien Carbonez², Jean E. Rubay¹, Thierry Detaille³, Laurent Houtekie³, Mona Momeni⁴

Congenital Heart Disease, Vol.18, No.2, pp. 151-168, 2023, DOI:10.32604/chd.2023.022636

Abstract Background: Most outcome studies in congenital cardiac surgery for “low weight” neonates include patients undergoing surgery without cardiopulmonary bypass (CPB). The primary objective of our study was to identify risk factors for in-hospital mortality in neonates weighing less than 3 Kg and undergoing surgery with CPB. In addition, we compared the effect of early surgery with CPB (before 37W-gestational age (GA)) for congenital heart disease to delayed surgery until a corrected GA of 37 weeks in an attempt to promote weight gain. Methods: Retrospective single-center study including all patients operated between 1997 and 2017. Uni- and multivariable analysis were used… More >

Huihui Zhang, Jing Yan, Xiaoyong Ren, Ying Sheng, Zhenghui Wang, Jianmin Liang, Yan Yan, Yangyang Jia, Zhihui Li, Jin Hou^*

Oncologie, Vol.24, No.4, pp. 707-716, 2022, DOI:10.32604/oncologie.2022.027023

Abstract Objective: To assess the efficacy and toxicity of nimotuzumab combined with neoadjuvant or induction chemotherapy for head and neck squamous cell carcinoma (HNSCC). Methods: Patients received intravenous nimotuzumab (400 mg, weekly for 1–3 weeks) combined with chemotherapy (5-fluorouracil/paclitaxel/docetaxel + nedaplatin/cisplatin for 1–2 cycles), prior to definitive surgical resection, radiotherapy or other treatments. The primary endpoint was the objective response rate (ORR). The secondary endpoints were tumor downstaging, complete response rate (CRR), partial response rate (PRR), disease control rate (DCR), R0 resection rate, pathological complete response (pCR), larynx preservation rate, overall survival (OS), progression-free survival (PFS), and safety. Results: A total… More >

Xujie Zhou^1,2,3,#, Yuting Sang^1,3,#, Jiajian Chen^1,3, Miao Mo^3,4, Jianjing Hou^1,3, Benlong Yang^1,3,*, Jiong Wu^1,2,3,*

Oncologie, Vol.24, No.3, pp. 451-469, 2022, DOI:10.32604/oncologie.2022.025226

Abstract Background: To compare the time-varying recurrence patterns of different molecular subtypes of breast cancer in the contemporary era with those in the past era. Patients and Methods: This retrospective study included 14627 consecutive invasive breast cancer patients who underwent surgery from 2008 to 2016 at Fudan University Shanghai Cancer Center. We defined the period from 2013 to 2016 as the contemporary era and that from 2008 to 2012 as the past era. Five subtypes were defined according to the immunohistochemistry results. Emphasis was made on the changing patterns of recurrence for patients with different molecular subtypes changed between the two… More >

Jing Tang^*1, Xu Yong Li^†1, Jing Bo Liang^‡, De Wu^§, Li Peng^¶, Xiaobing Li^¶

Oncology Research, Vol.27, No.6, pp. 635-641, 2019, DOI:10.3727/096504018X15288447760357

Abstract Apatinib is an oral TKI with antiangiogenic properties, and it is currently approved for the treatment of advanced gastric cancer in China. This agent has also been tested in other human solid tumors, including non-small cell lung cancer (NSCLC). Since the combination of chemotherapy and an antiangiogenic agent has been shown to be a feasible strategy in NSCLC, it is conceivable that a similar approach combining apatinib with chemotherapy may yield clinical activity. With this in mind, we investigated the efficiency of apatinib in combination with pemetrexed or docetaxel in advanced NSCLC. We treated a total of 20 patients with… More >

Xiaoting Wei, Lili Mao, Zhihong Chi, Xinan Sheng, Chuanliang Cui, Yan Kong, Jie Dai, Xuan Wang, Siming Li, Bixia Tang, Bin Lian, Xieqiao Yan, Xue Bai, Li Zhou, Jun Guo, Lu Si

Oncology Research, Vol.27, No.4, pp. 495-501, 2019, DOI:10.3727/096504018X15331163433914

Abstract Melanoma is an aggressive malignancy with a poor prognosis. Current studies show that imatinib treatment is a promising approach in treating advanced melanoma patients harboring c-Kit mutations or amplifications. We retrospectively analyzed the clinical medical records of 78 patients with metastatic melanoma harboring c-Kit mutations or amplifications. These patients were treated with imatinib at a dose of 400 mg/day continuously unless intolerable toxicities or disease progression occurred. Endpoints for exploration included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease of control rate (DCR). The median OS and PFS of all patients were 13.1 and 4.2 months,… More >

Vitaliy Suvorov^1,*, Vladimir Zaitcev¹, Karolina Andrzejczyk²

Congenital Heart Disease, Vol.17, No.3, pp. 365-374, 2022, DOI:10.32604/chd.2022.019126

Abstract Background: Bilateral banding of the branches of the pulmonary artery in patients with hypoplastic left heart syndrome (HLHS) and other duct dependent critical neonatal heart malformations can significantly reduce the incidence of severe complications in the postoperative period, especially in severely unstable patients. In our study we compared different surgical techniques of bilateral pulmonary artery banding (PAB) in respect to their success in balancing systemic and pulmonary blood flow. Methods: We included 44 neonates with a HLHS and congenital heart diseases (CHD) with a functional single ventricle underwent a hybrid operation: bilateral PAB and patent ductus arteriosus stenting. The hybrid… More >

Se Yong Jung^#, Doyoung Jung^#, Ah Young Kim, Jae Hee Seol, Jung Min Park, Jo Won Jung, Jae Young Choi^*

Congenital Heart Disease, Vol.16, No.3, pp. 233-244, 2021, DOI:10.32604/CHD.2021.014272

Abstract Purpose: This study examined the efficacy and safety of selexipag in treating pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD). Materials and Methods: We conducted a retrospective study of patients with CHD-associated PAH, treated with selexipag since December 2017. Thirteen adult patients (mean age, 45.4 years; women, 77%) were treated with selexipag as add-on therapy. Baseline characteristics, World Health Organization functional class, 6-minute walking distance (6MWD) test results, N-terminal pro-B-type natriuretic peptide levels, echocardiographic data, and incidence of side effects were assessed. Results: The majority of patients (12/13, 92.3%) experienced more than one treatment-associated complication; one patient dropped… More >

Fadhila Mansour^1,2,*, Abdelhak Lakehal^2,3, Lahcène Nezzal^2,3

Oncologie, Vol.22, No.3, pp. 117-128, 2020, DOI:10.32604/oncologie.2020.014979

Abstract The objective of this study was to quantify the delays in access to diagnosis and treatment of women with breast cancer who are managed at the anticancer center of Batna, Algeria. This was a descriptive retrospective study conducted during the period August 2015 to February 2016. In order to trace the history of the journey from the first signs of cancer to the first treatments, a questionnaire was filled in from the medical files and completed by an interview with the patients. A total of 267 patients were included in the study. The median time to management was 4.5 months.… More >